Table 1.
Patient characteristics overall and by refined DRI group
| Variable | All patients (n = 372) | Low risk (n = 71) | Intermediate risk (n = 241) | High/very high risk* (n = 60) | P† |
|---|---|---|---|---|---|
| Patient age, y | |||||
| Median (range) | 55 (18-75) | 52 (18-72) | 56 (18-75) | 58 (19-72) | .009‡ |
| Age ≥60 y, N | 131 (35%) | 15 (21%) | 93 (39%) | 23 (38%) | |
| Male gender, N | 244 (66%) | 50 (70%) | 154 (64%) | 40 (67%) | .61 |
| Histology, N | |||||
| Myeloid | 120 (32%) | 18 (25%) | 79 (33%) | 23 (38%) | .37 |
| Lymphoid | 247 (66%) | 53 (75%) | 158 (66%) | 36 (60%) | |
| Biphenotypic§ | 5 (1%) | 0 (0%) | 4 (2%) | 1 (2%) | |
| Diagnosis | |||||
| Acute leukemia or lymphoblastic lymphoma | 114 (31%)|| | 11 (15%) | 81 (34%) | 22 (37%) | |
| MDS/MPN | 35 (9%) | 7 (10%) | 19 (8%) | 9 (15%) | |
| Aggressive NHL¶ | 95 (26%) | 0 (0%) | 85 (35%) | 10 (16%) | |
| Mantle cell lymphoma | 29 (8%) | 11 (15%) | 14 (6%) | 4 (7%) | |
| Indolent NHL, CLL, or MM# | 62 (17%) | 32 (45%) | 28 (12%) | 2 (3%) | |
| HL | 37 (10%) | 10 (14%) | 14 (6%) | 13 (22%) | |
| Year of BMT, N | |||||
| 2002-2008 | 154 (41%) | 36 (51%) | 85 (35%) | 33 (55%) | .005 |
| 2009-2012 | 218 (59%) | 35 (49%) | 156 (65%) | 27 (45%) | |
| HCT-CI risk score, N | |||||
| 0 (low risk) | 98 (26%) | 25 (35%) | 56 (23%) | 17 (28%) | .19 |
| 1-2 (intermediate risk) | 137 (37%) | 27 (38%) | 91 (38%) | 19 (32%) | |
| ≥3 (high risk) | 137 (37%) | 19 (27%) | 94 (39%) | 24 (40%) | |
| Comorbidity-age index, N | |||||
| 0-2 (low risk) | 184 (49%) | 44 (61%) | 109 (45%) | 31 (52%) | .04 |
| ≥3 (high risk) | 188 (51%) | 27 (39%) | 132 (55%) | 29 (48%) | |
| Prior autologous BMT, N | 71 (19%) | 13 (18%) | 43 (18%) | 15 (25%) | .43 |
| Patient CMV serostatus, N | |||||
| CMV negative | 198 (53%) | 39 (55%) | 124 (51) | 35 (58%) | .59 |
| CMV positive | 171 (46%) | 30 (42%) | 116 (48) | 25 (42%) | |
| Unknown | 3 (1%) | 2 (3%) | 1 (1%) | 0 (0%) | |
| CMV matching, N | |||||
| Match | 225 (60%) | 40 (56%) | 150 (62%) | 35 (58%) | .68 |
| Mismatch | 143 (38%) | 29 (41%) | 89 (37%) | 25 (42%) | |
| Unknown | 4 (1%) | 2 (3%) | 2 (1%) | 0 (0%) | |
| Donor age (y), median (range) | 41 (13-79) | 42 (17-69) | 40 (13-79) | 41 (22-73) | .53‡ |
| Female donor for male patient, N | 103 (28%) | 19 (27%) | 65 (27%) | 19 (32%) | .76 |
| Cell dose infused, median (IQR) | |||||
| TNC × 108/kg | 4.12 (3.4-4.7) | 4.18 (2.7-4.7) | 4.18 (3.5-4.8) | 3.89 (3.2-4.3) | .07‡ |
| CD34+ cells × 106/kg | 4.05 (3.2-5.2) | 3.55 (3.2-4.8) | 4.29 (3.2-5.3) | 3.86 (3.3-5.3) | .18‡ |
| CD3+ cells × 107/kg | 3.84 (3.1-4.8) | 3.98 (3.2-4.8) | 3.86 (3.1-4.8) | 3.69 (2.8-4.5) | .22‡ |
CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; HL, Hodgkin lymphoma; IQR, interquartile range; MM, multiple myeloma; MPN, myeloproliferative neoplasm; TNC, total nucleated cells.
*
Fifty cases (13%) were high-risk, and 10 cases (3%) were very high risk.
†
P for differences between refined DRI risk groups.
‡
P using nonparametric methods.
§
Analyzed as AML.
||
Includes 90 cases (24%) of AML (57 cases de novo) and 24 cases (6%) of acute lymphoblastic leukemia/lymphoma. All percentages are for column-wise comparisons unless otherwise noted.
¶
Includes follicular grade 3 lymphoma and excludes lymphoblastic lymphoma.
#
Excludes transformed lymphoma.